Johnson & Johnson submits supplemental Biologics License Application to U.S. FDA seeking approval of TREMFYA (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis Read more
SK bioscience Breaks Ground on Manufacturing Facility Expansion for Extending Product Pipeline Read more
FDA Approves Opdivo (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma Read more
Sionna Therapeutics Announces $182 Million Series C Financing to Advance Clinical Development of Novel Small Molecules in Cystic Fibrosis Read more
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers Read more
Johnson & Johnson submits application to the European Medicines Agency for DARZALEX (daratumumab)-based quadruplet therapy for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma Read more
Sandoz acquires CIMERLI business from Coherus, further building biosimilar and ophthalmology leadership in US market Read more
FogPharma Announces $145 Million Financing to Support Ongoing Clinical Development of FOG-001 and Accelerate Helicon Peptide Portfolio Read more